DERMATOLOGY UPDATE SPONSOR Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd. is the world’s fourth largest specialty generic pharmaceutical company. A vertically integrated business and a skilled team enables us to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Our global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 7% of annual revenues in R&D.

We are pleased to have expanded into Canada, establishing a Sun Pharma Canada Inc. affiliate. We have launched tildrakizumab (PrILUMYA®️), an IL-23 p19inhibitor for moderate-to-severe plaque psoriasis, and have more dermatology products in the pipeline. We look forward to sharing more about these treatment options in the near future. Our goal is to demonstrate our commitment in Dermatology and working in close partnership with the Canadian Healthcare System and Patients.

Are you a dermatologist or a family physician?

Enjoy a complimentary e-subscription to SkinTherapyLetter®, a prestigious Dermatology journal indexed with the National Library in Washington.

Subscribe Today!